Astronics price target raised to $21 from $18 at Truist

Truist raised the firm’s price target on Astronics to $21 from $18 and keeps a Hold rating on the shares after its Q4 results. The company’s earnings and guided revenue were in line with the January pre-announcement, while its Aero margins improved significantly, the analyst tells investors in a research note. MAX-related issues have driven some delays, but sales, margins, and free cash flow generation should begin to pick up in Q2, the firm added.